Welcome to our dedicated page for Neubase Therapeutics news (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on Neubase Therapeutics stock.
Neubase Therapeutics Inc (NASDAQ: NBSE) is a biotechnology innovator focused on developing precision therapies for rare genetic disorders through its modular antisense platform. This page serves as the definitive source for all company announcements, research milestones, and financial updates.
Investors and researchers can access timely updates on clinical trial progress, strategic partnerships, and scientific advancements in gene silencing technology. Our curated news provides transparent insights into NBSE's efforts to address conditions like Huntington's disease through targeted genetic solutions.
Key content includes earnings reports, regulatory filings, technology patents, and collaboration announcements. Each update is verified for accuracy to support informed decision-making in genetic medicine.
Bookmark this page for direct access to Neubase's official communications. Check regularly for new insights into one of biotechnology's most promising approaches to treating inherited disorders.
NeuBase Therapeutics (Nasdaq: NBSE) reported its Q1 fiscal 2023 results on February 14, 2023. The company had approximately $17.4 million in cash and cash equivalents, down from $23.2 million in the prior quarter, sufficient to fund operations into Q2 2024. They reported a net loss of $4.4 million or $0.13 per share, an improvement from a $7.7 million loss or $0.24 per share year-over-year. NeuBase is advancing its PATrOL™ platform for gene editing, announcing collaborations and research agreements with global healthcare companies focused on genetic diseases. The company plans to disclose more data and progress throughout 2023.
NeuBase Therapeutics (Nasdaq: NBSE) announced its financial results for the fiscal year ending September 30, 2022, reporting a net loss of $33.8 million, or $1.04 per share, up from a $25.4 million loss in the previous year. As of September 30, 2022, cash reserves were approximately $23.2 million. The company is reducing investments in gene silencing programs while exploring partnerships to advance its developmental pipeline. NeuBase aims to enhance its gene editing technology platform, PATrOL™, which shows promise in treating genetic diseases through precise mutation correction.
NeuBase Therapeutics (Nasdaq: NBSE) has entered a research agreement with a Top 10 Global Healthcare company to evaluate its PATrOL™ technology for three monogenic genetic diseases. The PATrOL™ platform aims to address genetic disorders by using PNA-based gene editing, which is designed to increase fidelity and reduce immunogenicity compared to traditional methods like CRISPR-Cas9. The collaboration will explore novel drug candidates, providing the Healthcare Company with potential exclusive licensing opportunities based on the evaluation outcomes.
NeuBase Therapeutics (Nasdaq: NBSE) has announced a major restructuring aimed at enhancing cash flow and shareholder value. Key measures include a workforce reduction of approximately 60% and a focus on its gene editing platform while cutting back on R&D for myotonic dystrophy type 1 and Huntington's disease programs. The company expects this cost-saving plan to extend its cash runway into Q2 CY2024. CEO Dietrich A. Stephan emphasized the intention to prioritize advancements in gene editing technology, which is anticipated to improve the company’s long-term prospects.
NeuBase Therapeutics (Nasdaq: NBSE) announced participation in Chardan’s 6th Annual Genetic Medicines Conference on October 3-4, 2022, in New York City. Management will engage in a fireside chat on October 3rd from 9:00 AM to 9:25 AM ET. The presentation will be accessible via webcast, with a replay available for 90 days. NeuBase is focused on innovative precision genetic medicines, leveraging its proprietary PATrOL™ platform to target disease-causing mutations in serious conditions.
NeuBase Therapeutics (NBSE) reported progress in its myotonic dystrophy type 1 (DM1) and Huntington's disease (HD) programs, showcasing promising pharmacokinetics and biodistribution data at the ASGCT Annual Meeting. The company plans further preclinical studies, delaying the Investigational New Drug (IND) submission for DM1 to mid-2023. Financially, NeuBase had $29.8 million in cash as of June 30, 2022, with a net loss of $8.5 million for the quarter. Its total operating expenses decreased slightly from the previous year.
NeuBase Therapeutics (NASDAQ: NBSE) announced the promotion of Dr. William Mann to President, effective immediately. Dr. Mann, who will also retain his role as Chief Operating Officer, has been integral to advancing NeuBase's PATrOL™ platform since joining in July 2020. His previous leadership roles include transforming Helsinn Therapeutics U.S. into a profitable entity. NeuBase focuses on developing precision genetic medicines aimed at addressing genetic disorders, including myotonic dystrophy and KRAS-driven cancers.
